People and Business News — 7/22
People News
CSOFT Health Sciences announced its appointment of Vladimir Misik, PhD as Vice President of Global Clinical Strategy.
The Pistoia Alliance announced Becky Upton,PhD as its first female president.
Chris Schoonmaker has joined PHASTAR as Chief Operations Officer.
eClinical Solutions named Venu Mallarapu as their new Vice President of Strategy and Global Operations.
Saama Technologies, LLC announced that Vivek Sharma has joined the company as Chief Executive Officer.
Walgreens announced the hiring of the following: Kendal Whitlock as Head of Digital Optimization, Real World Evidence Clinical Trials; John Campbell as Head of Decentralized Clinical Trials; Liam Wood as Head of Product, Clinical Trials; and Adam Samson as Head of Clinical Delivery Operations, Clinical Trials.
Clario announced that Christopher Fikry, MD has begun his tenure as CEO.
Noel Alaka joined COTA, Inc. as Vice President of Life Sciences.
Business News
MMS Holdings has been selected by MAPS Public Benefit Corporation (MAPS PBC) as its CRO for the development of a New Drug Application for MDMA-assisted therapy for posttraumatic stress disorder.
HeartcoR Solutions announced it has relocated from Algonquin, IL to Schaumburg, IL.
Sharp has expanded its clinical services offering at its Heerenveen facility in the Netherlands.
SGS’s Quay Pharma will open its new pharmaceutical development and clinical manufacturing facility in Hudson, NH.
Recognition
Emmes researchers contributed to a successful AIDS Malignancy Consortium study and the results were published in the New England Journal of Medicine.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
